{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:29:54Z","timestamp":1791952194723,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ctrv.2026.103093","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T16:23:12Z","timestamp":1768234992000},"page":"103093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+\/HER2\u2013 advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"143","author":[{"given":"Najwaa","family":"Kirmani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalia","family":"De Le\u00f3n-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan David","family":"Rodriguez-Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bezalel","family":"Hakkeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7886-2565","authenticated-orcid":false,"given":"Clara","family":"Brice\u00f1o-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena","family":"Brice\u00f1o-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctrv.2026.103093_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clinicians"},{"key":"10.1016\/j.ctrv.2026.103093_b0010","unstructured":"SEER*Explorer Application. Accessed October 21, 2025. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/index.html."},{"issue":"35","key":"10.1016\/j.ctrv.2026.103093_b0015","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"JCO"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103093_b0020","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1200\/JCO.23.02036","article-title":"Randomized phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-positive, Human Epidermal Growth factor Receptor 2\u2013Negative Advanced Breast Cancer: Primary results from AMEERA-5","volume":"42","author":"Cort\u00e9s","year":"2024","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103093_b0025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103093_b0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-023-00523-4","article-title":"An emerging generation of endocrine therapies in breast cancer: a clinical perspective","volume":"9","author":"Patel","year":"2023","journal-title":"npj Breast Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103093_b0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2026.103093_b0040","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1200\/JCO.2020.38.15_suppl.1010","article-title":"Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: an exploratory analysis of the PADA-1 trial","volume":"38","author":"Bidard","year":"2020","journal-title":"JCO"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103093_b0045","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1200\/JCO.22.02746","article-title":"AMEERA-3: Randomized phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-positive, Human Epidermal Growth factor Receptor 2\u2013Negative Advanced Breast Cancer","volume":"41","author":"Tolaney","year":"2023","journal-title":"JCO"},{"issue":"15","key":"10.1016\/j.ctrv.2026.103093_b0050","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.3390\/ijms22157812","article-title":"Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective","volume":"22","author":"Hernando","year":"2021","journal-title":"IJMS"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103093_b0055","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103093_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1385577","article-title":"Next generation selective estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptors-positive, HER2-negative breast cancer","volume":"14","author":"Sharaf","year":"2024","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103093_b0065","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/0008-5472.CAN-24-2608","article-title":"Imlunestrant is an oral, brain-penetrant selective estrogen receptor degrader with potent antitumor activity in ESR1 Wild-type and mutant breast cancer","volume":"85","author":"Bhagwat","year":"2025","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103093_b0070","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.188051","article-title":"Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor\u2013positive breast cancer","volume":"10","author":"Sherman","year":"2025","journal-title":"JCI Insight"},{"issue":"32","key":"10.1016\/j.ctrv.2026.103093_b0075","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1080\/14796694.2024.2377530","article-title":"VERITAC-2: a phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2- advanced breast cancer","volume":"20","author":"Hamilton","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2026.103093_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103093_b0085","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.23.02112","article-title":"US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-positive, Human Epidermal Growth factor Receptor 2\u2013Negative, ESR1 -Mutated Advanced or Metastatic Breast Cancer","volume":"42","author":"Shah","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103093_b0090","unstructured":"https:\/\/www.nice.org.uk\/guidance\/ta1036."},{"issue":"11","key":"10.1016\/j.ctrv.2026.103093_b0095","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.annonc.2025.07.017","article-title":"Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer living Guideline","volume":"36","author":"Trapani","year":"2025","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103093_b0100","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1 -mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103093_b0105","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103093_b0110","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103093_b0115","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.23.01500","article-title":"Giredestrant for Estrogen Receptor-positive, HER2-negative, previously Treated Advanced Breast Cancer: results from the Randomized, phase II acelERA Breast Cancer Study","volume":"42","author":"Mart\u00edn","year":"2024","journal-title":"JCO"},{"issue":"28","key":"10.1016\/j.ctrv.2026.103093_b0120","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-positive, Human Epidermal Growth factor Receptor 2\u2013Negative Advanced Breast Cancer: results from the Randomized phase III EMERALD Trial","volume":"40","author":"Bidard","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103093_b0125","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Accessed March 23, 20https:\/\/training.cochrane.org\/handbook."},{"key":"10.1016\/j.ctrv.2026.103093_b0130","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"n71","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2026.103093_b0135","unstructured":"RoB 2: A revised Cochrane risk-of-bias tool for randomized trials | Cochrane Bias. Accessed June 13, 2025. https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials."},{"issue":"3","key":"10.1016\/j.ctrv.2026.103093_b0140","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12282-011-0276-3","article-title":"Improvement of survival and prospect of cure in patients with metastatic breast cancer","volume":"19","author":"Cheng","year":"2012","journal-title":"Breast Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103093_b0145","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13058-024-01881-y","article-title":"Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysis","volume":"26","author":"Morgan","year":"2024","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103093_b0150","doi-asserted-by":"crossref","unstructured":"The ICBP Module 1 Working Group20, Walters S., Maringe C., Butler J., Rachet B., Barrett-Lee P., et al. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. Br J Cancer. 108(5) (2013) 1195\u2013208. https:\/\/doi.org\/10.1038\/bjc.2013.6.","DOI":"10.1038\/bjc.2013.6"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103093_b0155","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1093\/oncolo\/oyab023","article-title":"Factors associated with time to progression and overall survival in patients with de novo metastatic breast cancer: a Colombian cohort","volume":"27","author":"D\u00edaz-Casas","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103093_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-323-35955-9.00022-2","article-title":"Molecular oncology of breast cancer","author":"Joshi","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2026.103093_b0165","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 8.2021."},{"issue":"10","key":"10.1016\/j.ctrv.2026.103093_b0170","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","article-title":"Therapeutic resistance to anti-oestrogen therapy in breast cancer","volume":"23","author":"Will","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2026.103093_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111322","article-title":"Mechanisms of endocrine therapy resistance in breast cancer","volume":"532","author":"Rasha","year":"2021","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103093_b0180","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103093_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102825","article-title":"Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review","volume":"130","author":"Gheysen","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103093_b0190","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3390\/cancers16030619","article-title":"Oral SERD, a novel endocrine therapy for estrogen receptor-positive breast cancer","volume":"16","author":"Neupane","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2026.103093_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102569","article-title":"Novel endocrine therapies: what is next in estrogen receptor positive, HER2 negative breast cancer?","volume":"117","author":"Corti","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103093_b0200","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-1073","article-title":"Elacestrant in ER+, HER2\u2212 metastatic breast cancer with ESR1 -mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4\/6 inhibitor and in clinical subgroups","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103093_b0205","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10555-022-10066-y","article-title":"The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options","volume":"41","author":"Wang","year":"2022","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103093_b0210","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-14-0697","article-title":"Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer","volume":"5","author":"Van Kruchten","year":"2015","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103093_b0215","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/14737140.2025.2479604","article-title":"Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4\/6 inhibitors","volume":"25","author":"Sahin","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2026.103093_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103729","article-title":"Oral SERDs alone or in combination with CDK 4\/6 inhibitors in breast cancer: current perspectives and clinical trials","volume":"75","author":"Apostolidou","year":"2024","journal-title":"Breast"},{"issue":"8042","key":"10.1016\/j.ctrv.2026.103093_b0225","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08035-2","article-title":"Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer","volume":"636","author":"Sonke","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103093_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116051","article-title":"Health economic outcomes and costs of CDK4\/6 inhibitor use in first- versus second-line for advanced breast cancer: a cost-effectiveness analysis of the phase 3 SONIA trial","volume":"231","author":"Wortelboer","year":"2025","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103093_b0235","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1158\/1078-0432.CCR-21-1095","article-title":"A phase I study of LSZ102, an oral selective estrogen receptor degrader, with or without ribociclib or alpelisib, in patients with estrogen receptor-positive breast cancer","volume":"27","author":"Jhaveri","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.ctrv.2026.103093_b0240","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1002\/cam4.2453","article-title":"Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant","volume":"8","author":"He","year":"2019","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103093_b0245","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1200\/JOP.18.00518","article-title":"Financial toxicity in advanced and metastatic cancer: overburdened and underprepared","volume":"15","author":"Rotter","year":"2019","journal-title":"JOP"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103093_b0250","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2016.66.6313","article-title":"Use and costs of Disease monitoring in Women with Metastatic Breast Cancer","volume":"34","author":"Accordino","year":"2016","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103093_b0255","unstructured":"European Organisation for Research and Treatment of Cancer - EORTC. Elacestrant for Treating ER+\/HER2- Breast Cancer Patients With ctDNA Relapse. 2025."},{"key":"10.1016\/j.ctrv.2026.103093_b0260","unstructured":"AstraZeneca. CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+\/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence. 2025."},{"key":"10.1016\/j.ctrv.2026.103093_b0265","unstructured":"AstraZeneca. CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+\/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease. 2025."},{"key":"10.1016\/j.ctrv.2026.103093_b0270","article-title":"Multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early","author":"Hoffmann-La Roche","year":"2025","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103093_b0275","unstructured":"Eli Lilly and Company. EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence. 2025."},{"key":"10.1016\/j.ctrv.2026.103093_b0280","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-med-052423-122001","article-title":"New oral selective estrogen receptor degraders redefine management of estrogen receptor-positive breast cancer","volume":"76","author":"Pathak","year":"2025","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103093_b0285","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12885-023-11722-4","article-title":"The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on\u2265 1 line of endocrine therapy: systematic review and meta-analysis","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Cancer"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:56:47Z","timestamp":1770479807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":57,"alternative-id":["S0305737226000071"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103093","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+\/HER2\u2013 advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103093"}}